-
Published on Oct 17, 2016
Clinical
services specialist Ergomed Plc (LON:ERGO) has announced that its
co-development partner AEterna Zentaris Inc (TSE:AEX, NASDAQ:AEZS) has
signed an additional licensing deal for cancer drug Zoptrex.
AEterna will receive an up-front payment plus milestone payments and royalties, while Ergomed will receive a portion of all revenues generated from the commercialisation of the product
Chief business officer Andrew Mackie said the drug has the potential to be launched globally. His expectation is that AEterna Zentaris is holding back much of Europe and the US until after a report on the Phase III results. He says it's then that they'll make a commercialisation decision whether they want to take the product to market themselves or whether they want to find further partners in Europe and the US.
http://www.4-traders.com/ERGOMED-PLC-16917574/
www.ergomedplc.com/investor-relations/investor_relations/
AEterna will receive an up-front payment plus milestone payments and royalties, while Ergomed will receive a portion of all revenues generated from the commercialisation of the product
Chief business officer Andrew Mackie said the drug has the potential to be launched globally. His expectation is that AEterna Zentaris is holding back much of Europe and the US until after a report on the Phase III results. He says it's then that they'll make a commercialisation decision whether they want to take the product to market themselves or whether they want to find further partners in Europe and the US.
http://www.4-traders.com/ERGOMED-PLC-16917574/
www.ergomedplc.com/investor-relations/investor_relations/
Ergomed PLC $ERGO Stock Rating Reaffirmed by Numis Securities Ltd https://t.co/mBvR0QlKCB— US Consumer News (@ConsumerFeed) October 17, 2016
No comments:
Post a Comment